SF3B1 and myelodysplastic syndrome: Luspatercept, a recombinant fusion protein, has recently proven itself as a viable treatment option in patients with low-risk MDS with ringed sideroblasts (RS) and the spliceosome factor 3B1 (SF3B1) mutation [2, 3].